Yahoo
NSE - Delayed Quote INR

Aurobindo Pharma Limited (AUROPHARMA.NS)

1,681.40 +21.50 (+1.30%)
At close: October 30 at 3:28:19 PM GMT+5:30
View in AlphaSpace Currency in INR All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
3/31/2026
3/31/2025
3/31/2024
3/31/2023
Total Revenue
346,987,900
333,847,400
313,781,300
287,045,000
246,171,300
Cost of Revenue
147,126,600
143,249,300
137,415,200
132,362,100
118,997,000
Gross Profit
199,861,300
190,598,100
176,366,100
154,682,900
127,174,300
Operating Expense
145,967,400
138,669,400
125,885,500
110,267,600
101,798,300
Operating Income
53,893,900
51,928,700
50,480,600
44,415,300
25,376,000
Net Non Operating Interest Income Expense
-588,000
-548,900
-1,040,000
-39,500
54,100
Pretax Income
54,201,400
51,118,500
50,662,900
43,799,900
26,125,000
Tax Provision
17,093,400
16,088,800
15,827,200
12,110,200
6,848,500
Net Income Common Stockholders
37,125,600
35,047,500
34,858,800
31,729,700
19,275,000
Diluted NI Available to Com Stockholders
37,125,600
35,047,500
34,858,800
31,729,700
19,275,000
Basic EPS
64.00
60.34
59.81
54.16
32.90
Diluted EPS
64.00
60.34
59.81
54.16
32.90
Basic Average Shares
580,134.43
580,801.62
582,870.49
585,938.61
585,938.61
Diluted Average Shares
580,134.43
580,801.62
582,870.49
585,938.61
585,938.61
Rent Expense Supplemental
--
566,000
713,400
1,204,200
1,337,600
Total Expenses
293,094,000
281,918,700
263,300,700
242,629,700
220,795,300
Net Income from Continuing & Discontinued Operation
37,125,600
35,047,500
34,858,800
31,729,700
19,275,000
Normalized Income
38,636,034.59
36,284,055.32
35,491,254.48
33,810,268.95
19,354,176.67
Interest Income
--
3,290,800
3,532,400
2,857,600
1,458,900
Interest Expense
3,562,200
3,523,100
4,403,900
2,680,900
1,289,500
Net Interest Income
-588,000
-548,900
-1,040,000
-39,500
54,100
EBIT
57,763,600
54,641,600
55,066,800
46,480,800
27,414,500
EBITDA
76,181,300
72,248,100
70,978,800
61,399,900
39,860,300
Reconciled Cost of Revenue
147,126,600
143,249,300
137,415,200
132,362,100
118,997,000
Reconciled Depreciation
18,417,700
17,606,500
15,912,000
15,216,600
12,445,800
Net Income from Continuing Operation Net Minority Interest
37,125,600
35,047,500
34,858,800
31,729,700
19,275,000
Total Unusual Items Excluding Goodwill
-2,206,200
-1,804,400
-919,800
-2,875,700
-107,300
Total Unusual Items
-2,206,200
-1,804,400
-919,800
-2,875,700
-107,300
Normalized EBITDA
78,387,500
74,052,500
71,898,600
64,275,600
39,967,600
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-695,765.41
-567,844.68
-287,345.52
-795,131.05
-28,123.33
3/31/2023 - 1/15/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: